About Cullinan Therapeutics Inc
- Industry: Biotechnology
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://cullinantherapeutics.com/
Frequently Asked Questions
What is the 52-week range for CGEM?
The 52-week high is $23.19 and the 52-week low is $5.68.
What is the P/E ratio for CGEM?
The P/E ratio data is currently unavailable.
What is the dividend yield for CGEM?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is -52.89%.
What is the Net Profit Margin?
Net Margin data is currently unavailable.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 1.50.
Analyst Recommendation Trends
Wall Street analyst consensus for CGEM over the last few months:
Latest CGEM News
HC Wainwright & Co. Reiterates Buy on Cullinan Therapeutics, Maintains $35 Price Target
HC Wainwright & Co. analyst Robert Burns reiterates Cullinan Therapeutics (NASDAQ:CGEM) with a Buy and maintains $35 price target.
Reported Earlier, Cullinan Therapeutics Initiates NDA Submission For Zipalertinib Plus Chemotherapy In First-Line EGFR Exon 20 Insertion NSCLC Under FDA RTOR Program After Phase 3 REZILIENT3 Trial Met Primary Endpoint
In the Phase 3 REZILIENT3 study, zipalertinib combination therapy demonstrated longest median progression-free survival observed to date in first-line EGFR exon20ins NSCLC After agreement with the U.S. FDA, Real-Time
New Drug Application Submission Initiated for Zipalertinib Plus Chemotherapy in First-Line EGFR Exon 20 Insertion Mutation NSCLC for Review Under FDA Real-Time Oncology Review Program
In the Phase 3 REZILIENT3 study, zipalertinib combination therapy demonstrated longest median progression-free survival observed to date in first-line EGFR exon20ins NSCLC After agreement with the U.S. FDA, Real-Time Oncology Review program submission process initiated; completion of NDA submission expected by year-end 2026 CAMBRIDGE, Mass., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a clinical-stage biopharmaceutical company accelerating potential first- or be
Cullinan Therapeutics: Compelling Pullback For CLN-978's Potential In Autoimmune Diseases
Cullinan Therapeutics' stock pullback may be a strong entry ahead of December 2026 autoimmune updates. Read more on CGEM here.
Cullinan Therapeutics Eyes December Data Catalyst for CLN-978 and CLN-049
Cullinan Therapeutics (NASDAQ:CGEM) outlined upcoming clinical milestones across its immunology and oncology pipeline, including a planned December update for its CD19-directed T-cell engager CLN-978 and data presentations for other programs in November and the fourth quarter. President and CEO Nad
Cullinan Therapeutics (CGEM) Expects Three T Cell Engager Data Readouts In Q4 2026
Cullinan Therapeutics (NasdaqGS:CGEM) plans to report clinical data updates from three T cell engager programs in Q4 2026. The update will include new results for autoimmune and oncology candidates Velinotamig, CLN-978, and CLN-049. Cullinan also anticipates starting a Phase 2 study of CLN-049 after discussions with the US Food and Drug Administration. The planned Q4 2026 readouts and CLN-049 Phase 2 launch sit alongside a broader picture our research has uncovered. Take a look at 3 warning...
HC Wainwright & Co. Maintains Buy on Cullinan Therapeutics, Raises Price Target to $35
HC Wainwright & Co. analyst Robert Burns maintains Cullinan Therapeutics (NASDAQ:CGEM) with a Buy and raises the price target from $30 to $35.
BTIG Reiterates Buy on Cullinan Therapeutics, Maintains $40 Price Target
BTIG analyst Julian Harrison reiterates Cullinan Therapeutics (NASDAQ:CGEM) with a Buy and maintains $40 price target.
CGEM Stock Extends Losses After Cullinan Delays Arthritis Update To December — Zipalertinib Safety Worries Linger
Additional multi-dose data for CLN-978 in difficult-to-treat rheumatoid arthritis (RA), once expected in the third quarter, will now arrive in December.
Cullinan Therapeutics Plans Q4 2026 Clinical Data Updates Across Three T Cell Engager Programs
Cullinan Therapeutics, Inc. (NASDAQ:CGEM) plans to report clinical data from three T cell engager programmes during the fourth quarter of 2026, covering candidates being evaluated in autoimmune diseases and acute myeloid leukaemia.
Cullinan Therapeutics Highlights Fourth Quarter 2026 Milestones Across Immunology and Oncology T Cell Engager Portfolio
Velinotamig (BCMA TCE) multi-dose regimen data in SLE at ACR Convergence 2026 in November CLN-978 (CD19 TCE) multi-dose regimen data in SLE, RA and Sjögren’s disease in December CLN-049 (FLT3 TCE) updated data from the Phase 1 dose escalation study in December CAMBRIDGE, Mass., Sept. 24, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM; “Cullinan”), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, disease-modifying T cell engagers in au
Cullinan Therapeutics (CGEM) Could Be 50% Below Fair Value On Phase 3 Zipalertinib Data
Cullinan Therapeutics stock moves after Phase 3 zipalertinib data Cullinan Therapeutics (CGEM) is back in focus after Phase 3 REZILIENT3 trial results showed zipalertinib plus chemotherapy improved progression free survival for EGFR exon 20 insertion non small cell lung cancer patients. Recent trading tells a mixed story for Cullinan Therapeutics. The share price has fallen about 22% over the past day and over the last month, and is down close to 9% over 90 days. However, the year to date...
Cullinan Therapeutics (CGEM) Is Down 18.2% After Strong Zipalertinib Phase 3 Lung Cancer Data Release – Has The Bull Case Changed?
Taiho Pharmaceutical, Taiho Oncology and Cullinan Therapeutics recently reported that the Phase 3 REZILIENT3 trial of investigational EGFR inhibitor zipalertinib plus chemotherapy in previously untreated EGFR exon 20 insertion-positive advanced non-small cell lung cancer met its primary endpoint, delivering a statistically significant 6.0‑month median progression‑free survival improvement over chemotherapy alone with no new safety signals identified. For Cullinan, these late‑breaking data...
The Biggest Losers In Biotech — And It Had Nothing To Do With 'Compelling,' 'Best-In-Disease' Data
Biotech stocks widely slumped Wednesday, with Rapport Therapeutics, Climb Bio and Cullinan Therapeutics among some of the hardest-hit names.
Cullinan Therapeutics to Participate in the Stifel 2026 Virtual Immunology and Inflammation Forum
CAMBRIDGE, Mass., Sept. 21, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM; “Cullinan”), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, disease-modifying T cell engagers in autoimmune diseases and cancer, today announced that Nadim Ahmed, Chief Executive Officer, and Jeffrey Jones, M.D., M.B.A., Chief Medical Officer, will participate in a fireside chat at the Stifel 2026 Virtual Immunology and Inflammation Forum on Thursday, Septem
Cullinan Therapeutics (CGEM) Reports a Six-Month PFS Gain. Can it Justify Higher Toxicity?
Cullinan Therapeutics, Inc. (NASDAQ:CGEM) disclosed detailed Phase 3 REZILIENT3 results on September 13, 2026, in patients with previously untreated, locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations. Zipalertinib plus chemotherapy achieved median progression-free survival of 14.5 months, compared with 8.5 months for chemotherapy alone. Progression-free survival, or […]
Cullinan Therapeutics, Inc. (CGEM) Shareholder/Analyst Call - Slideshow
2026-09-14. The following slide deck was published by Cullinan Therapeutics, Inc.
Cullinan Therapeutics Shares Fall 6.3% After Phase 3 Zipalertinib Trial Results
Cullinan Therapeutics (NASDAQ:CGEM) shares fell 6. 3% on Monday after the company and its partners reported Phase 3 results for zipalertinib in patients with a form of non-small cell lung cancer.
Cullinan Therapeutics: The Market Shrugged At REZILIENT3, But Catalysts Await
Cullinan Therapeutics, Inc. gets a Hold as zipalertinib upside is limited; watch CLN-978 autoimmune catalysts, cash runway & dilution risk. Click for more on CGEM.
BTIG Maintains Buy on Cullinan Therapeutics, Raises Price Target to $40
BTIG analyst Julian Harrison maintains Cullinan Therapeutics (NASDAQ:CGEM) with a Buy and raises the price target from $39 to $40.
Cullinan Therapeutics, Inc. (CGEM) Shareholder/Analyst Call Transcript
Cullinan Therapeutics, Inc. (CGEM) Shareholder/Analyst Call September 14, 2026 8:00 AM EDTCompany ParticipantsNicholas Smith - Head of Investor...
Cullinan Therapeutics to Host Virtual Analyst and Investor Event Today to Feature Zipalertinib Plus Chemotherapy Phase 3 REZILIENT3 Data Presented at the IASLC 2026 World Conference on Lung Cancer
Company to host a virtual event today at 8:00 a.m. ETCAMBRIDGE, Mass., Sept. 14, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, disease-modifying T cell engagers in autoimmune diseases and cancer, today announced that it will host a virtual event for analysts and institutional investors today at 8:00 a.m. ET to discuss the results from the planned interim analysis of the Phase 3 REZIL
Reported Sunday, Taiho And Cullinan's REZILIENT3 Trial Meets Primary Endpoint, Zipalertinib Combination Shows PFS Hazard Ratio Of 0.50 Versus Chemotherapy Alone
Results from the Phase 3 REZILIENT3 trial were featured in a Presidential Symposium at WCLC 2026 and demonstrated a statistically significant improvement in progression-free survival in first-line EGFR exon 20 insertion
Zipalertinib Plus Chemotherapy Demonstrates 6-Month Median Progression-Free Survival Benefit in REZILIENT3 Phase 3 Trial in First-Line EGFR Exon 20 Insertion Mutation Non-Small Cell Lung Cancer
PRINCETON, N.J. & TOKYO & CAMBRIDGE, Mass., September 13, 2026--Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Cullinan Therapeutics, Inc. (Nasdaq: CGEM) today announced results from the Phase 3 REZILIENT3 trial evaluating zipalertinib plus chemotherapy versus chemotherapy alone in the first-line treatment of patients with epidermal growth factor receptor (EGFR) exon 20 insertion (ex20ins) mutation-positive non-small cell lung cancer (NSCLC). The data were presented at the Internation
Cullinan Therapeutics to Host Virtual Analyst and Investor Event to Showcase Zipalertinib Plus Chemotherapy Phase 3 REZILIENT3 Data Presented at the IASLC 2026 World Conference on Lung Cancer
Results from the planned interim analysis of the Phase 3 REZILIENT3 trial of zipalertinib plus chemotherapy in first-line EGFR exon 20 insertion mutation NSCLC to be presented in Presidential Symposium 2 on Sunday, September 13, 2026 Company to host a virtual event on Monday, September 14, 2026, at 8:00 a.m. ET CAMBRIDGE, Mass., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class,
Cullinan Therapeutics To Present Positive Phase 3 REZILIENT3 Results For Zipalertinib In EGFR Exon 20+ Lung Cancer; To Host A Virtual Event On Monday, September 14, 2026, At 8:00 a.m. ET
Results from the planned interim analysis of the Phase 3 REZILIENT3 trial of zipalertinib plus chemotherapy in first-line EGFR exon 20 insertion mutation NSCLC to be presented in Presidential Symposium 2 on Sunday,
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-09-08 | Michaelson Jennifer | -4,000 | - | - |
| 2026-09-08 | Michaelson Jennifer | -8,000 | $21.57 | $172,560 |
| 2026-09-08 | Michaelson Jennifer | +4,000 | $4.3 | $17,200 |
| 2026-08-13 | Michaelson Jennifer | -30,000 | - | - |
| 2026-08-13 | Michaelson Jennifer | -30,000 | $20.26 | $607,800 |
| 2026-08-13 | Michaelson Jennifer | +30,000 | $4.3 | $129,000 |
| 2026-07-06 | Michaelson Jennifer | -4,000 | - | - |
| 2026-07-06 | Michaelson Jennifer | -8,000 | $17.82 | $142,560 |
| 2026-07-06 | Michaelson Jennifer | +4,000 | $4.3 | $17,200 |
| 2026-06-30 | SUMER JACQUELYN L | +2,470 | $8.6 | $21,242 |
| 2026-06-30 | Fenton Mary Kay | +1,541 | $8.6 | $13,253 |
| 2026-06-16 | Meek David D. | +25,319 | - | - |
| 2026-06-16 | Rosenberg Anthony | +25,319 | - | - |
| 2026-06-16 | Webster Stephen W | +25,319 | - | - |
| 2026-06-16 | Allen Andrew R | +21,781 | - | - |
| 2026-06-16 | Thistle Mary | +25,319 | - | - |
| 2026-05-05 | Michaelson Jennifer | -4,000 | - | - |
| 2026-05-05 | Michaelson Jennifer | -200 | $15.58 | $3,116 |
| 2026-05-05 | Michaelson Jennifer | -7,800 | $14.6 | $113,880 |
| 2026-05-05 | Michaelson Jennifer | +4,000 | $4.3 | $17,200 |
| 2026-03-05 | Michaelson Jennifer | -4,000 | - | - |
| 2026-03-05 | Michaelson Jennifer | -8,000 | $15.68 | $125,440 |
| 2026-03-05 | Michaelson Jennifer | +4,000 | $4.3 | $17,200 |
| 2026-02-25 | Michaelson Jennifer | -1,780 | $14.14 | $25,169 |
| 2026-02-24 | Jones Jeffrey Alan | -4,582 | $14.47 | $66,302 |
| 2026-02-24 | SUMER JACQUELYN L | -3,601 | $14.47 | $52,106 |
| 2026-02-24 | Michaelson Jennifer | -3,601 | $14.47 | $52,106 |
| 2026-02-24 | AHMED NADIM | -13,515 | $14.47 | $195,562 |
| 2026-02-23 | Michaelson Jennifer | -1,752 | $13.99 | $24,510 |
| 2026-02-20 | Jones Jeffrey Alan | -4,982 | $13.62 | $67,855 |
| 2026-02-20 | Michaelson Jennifer | -8,000 | - | - |
| 2026-02-20 | Michaelson Jennifer | -8,000 | $14.3 | $114,400 |
| 2026-02-20 | Michaelson Jennifer | +8,000 | $4.3 | $34,400 |
| 2026-02-20 | Michaelson Jennifer | -3,742 | $13.62 | $50,966 |
| 2026-02-20 | SUMER JACQUELYN L | -3,742 | $13.62 | $50,966 |
| 2026-02-20 | AHMED NADIM | -16,381 | $13.62 | $223,109 |
| 2026-02-20 | Fenton Mary Kay | -4,398 | $13.62 | $59,901 |
| 2026-02-18 | SUMER JACQUELYN L | +230,000 | - | - |
| 2026-02-18 | Jones Jeffrey Alan | +300,000 | - | - |
| 2026-02-18 | Savill Corrine | +175,000 | - | - |
| 2026-02-18 | Michaelson Jennifer | +115,000 | - | - |
| 2026-02-18 | Michaelson Jennifer | +57,500 | - | - |
| 2026-02-18 | AHMED NADIM | +828,000 | - | - |
| 2026-02-18 | Fenton Mary Kay | +137,500 | - | - |
| 2026-02-18 | Fenton Mary Kay | +68,750 | - | - |
| 2026-02-12 | Michaelson Jennifer | -416 | $12.03 | $5,004 |
| 2026-01-22 | Michaelson Jennifer | -4,000 | $12.3 | $49,200 |
| 2025-12-31 | Fenton Mary Kay | +27 | $6.49 | $175 |
| 2025-12-23 | AHMED NADIM | -9,922 | $10.01 | $99,319 |
| 2025-12-19 | Michaelson Jennifer | -1,345 | $10.01 | $13,463 |
| 2025-12-18 | SUMER JACQUELYN L | -3,480 | $9.67 | $33,652 |
| 2025-12-18 | Jones Jeffrey Alan | -4,632 | $9.67 | $44,791 |
| 2025-12-18 | Michaelson Jennifer | -2,898 | $9.67 | $28,024 |
| 2025-12-15 | Michaelson Jennifer | -995 | $11.9 | $11,841 |
| 2025-12-12 | Michaelson Jennifer | -2,148 | $12.38 | $26,592 |
| 2025-11-24 | Michaelson Jennifer | -4,000 | $12.3 | $49,200 |
| 2025-10-28 | Nichols Weston | +165,667 | $8.4005 | $1,391,686 |
| 2025-10-17 | Nichols Weston | +32,217 | $7.8395 | $252,565 |
| 2025-10-16 | Nichols Weston | +150,000 | $8.855 | $1,328,250 |
| 2025-10-15 | Nichols Weston | +51,500 | $7.9427 | $409,049 |
| 2025-10-14 | Nichols Weston | +15,032 | $7.587 | $114,048 |
| 2025-10-10 | Nichols Weston | +277,298 | $7.3617 | $2,041,385 |
| 2025-10-09 | Nichols Weston | +626,043 | $6.6958 | $4,191,859 |
| 2025-10-08 | Nichols Weston | +556,300 | $6.46 | $3,593,698 |